alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Annals of clinical and translational neurology 2017-10-30 Treatments

    To review the optimality and safety of different anti-Amyloid- β (Aβ) immunotherapies for Alzheimer's disease (AD).

  2. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2015-04-27 Treatments

    The CAD106 first-in-human study demonstrated a favorable safety profile and promising antibody response.

  3. Risk of pneumonia in new users of cholinesterase inhibitors for dementia

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of the American Geriatrics Society 2015-04-27 Treatments

    The mean age of 35,570 new users of cholinesterase inhibitors (30,174 users of donepezil, 1,176 users of galantamine, 4,220 users of rivastigmine) was 82; 75% were women, and 82% were white.

  4. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. BMJ (Clinical research ed.) 2012-02-23 Health systems and care delivery

    Though these findings cannot prove causality, and we cannot rule out the possibility of residual confounding, they provide more evidence of the risk of using these drugs in older patients, reinforcing the concept that they should not be used in the absence of clear need.

  5. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2009-07-01 Digital health tools

    Our findings suggest that long-term use of BZDs is associated with an increased risk for dementia, but the underlying mechanisms remain unclear, and further investigations are needed.

  6. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006-03-01 Treatments

    Cognitive functioning, mood, and health-related QOL were significantly improved following a 24-week course of the acetylcholinesterase inhibitor donepezil.

  7. A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. JAMA 1997-10-22 Clinical trials

    Although modest, the changes induced by EGb were objectively measured by the ADAS-Cog and were of sufficient magnitude to be recognized by the caregivers in the GERRI.

  8. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 1997-06-01 Risk factors

    Previous reports have suggested that estrogen replacement therapy (ERT) in women may exert a protective effect on their risk of developing Alzheimer's disease (AD).

  9. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Archives of neurology 1994-09-01 Risk factors

    Alzheimer's disease case patients were significantly less likely than control subjects to use estrogen replacement (7% vs 18%), but groups did not differ with regard to the total number of prescription medications or to the most frequently prescribed class of drug (thyroid medication).

  10. Patient journey and decision processes for anti-amyloid therapy in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of neurology 2025-04-16 Treatments

    From an initial sample (N = 2499), 1064 patients (55,000 notes) were reviewed manually (mean age 76 years; 7.3% women; 9.2% Black; 3.9% Hispanic).

  11. Alzheimer's disease drug development pipeline: 2022

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia (New York, N. Y.) 2022-05-04 Drug development

    The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets.

  12. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01 Treatments

    Verubecestat is a potent BACE1 enzyme inhibitor currently being investigated in Phase III trials for the treatment of mild-to-moderate and prodromal Alzheimer's disease.

  13. Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of the American Geriatrics Society 2014-10-03 Digital health tools

    Taking more anticholinergic medications is associated with greater risk of hospitalization for confusion or dementia.

  14. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01 Treatments

    Cholinesterase inhibitors and memantine are able to stabilize or slow decline in cognition, function, behavior, and global change.

  15. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Nutrition & metabolism 2009-08-10 Clinical trials

    AC-1202 was compared to Placebo in several population groups, including: intention-to-treat (ITT), per protocol, and dosage compliant groups.

  16. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Neurology Neurosurgery & Psychiatry 2005-06-18 Treatments

    Donepezil was well tolerated and most adverse events were mild.

  17. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. BMJ (Clinical research ed.) 2005-02-18 Treatments

    Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care.

  18. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. BMJ (Clinical research ed.) 1999-03-01 Treatments

    At the end of the study cognitive function had deteriorated among those in the placebo group.

  19. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Sleep 2003-11-01 Risk factors

    Based on actigraphy as an objective measure of sleep time, melatonin is not an effective soporific agent in people with Alzheimer's disease.

  20. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Journal of neurology, neurosurgery, and psychiatry 2001-11-01 Treatments

    Patients on galantamine, compared with those on placebo, experienced benefits in cognitive function and instrumental and basic activities of daily living.

  21. Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. CPT: pharmacometrics & systems pharmacology 2024-08-29 Treatments

    Lecanemab (Leqembi®) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease upon confirmation of amyloid beta pathology.

  22. Alzheimer's disease drug development pipeline: 2024

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia (New York, N. Y.) 2024-04-24 Drug development

    Compared to the 2023 pipeline, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), fewer new chemical entities (88 vs. 101), and a similar number of repurposed agents (39 vs. 40).

  23. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Nature medicine 2023-09-07 Biomarkers

    Cellular senescence contributes to Alzheimer's disease (AD) pathogenesis.

  24. In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia (New York, N. Y.) 2022-06-06 Treatments

    Upon further refinement and validation, the VWD model could inform strategies for dosing and ARIA monitoring in individuals with an ARIA-E history.

  25. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Scientific reports 2022-03-15 Treatments

    Anti-dementia medications are widely prescribed to patients with Alzheimer's dementia (AD) in South Korea.

From across this topic

9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

Other topics